Program
sudapyridine
Also written as “Sudapyridine”, “[U-14C] WX-081” and “Sudapyridine 30mg”.
Its studies are mostly in Tuberculosis, Pulmonary · Tuberculosis, led by Shanghai Jiatan Pharmatech.
Furthest: phase 3, since Apr 10, 20235 company-led studies, 3 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Jiatan Pharmatech | 53 open or running | phase 3since Apr 10, 2023 | Oct 10, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2020First study: phase 2 study in Tuberculosis, PulmonaryFirst studyNCT04608955 · 99 enrolled · China
- Apr 10, 2023Phase 3 study in TuberculosisNCT05824871 · 450 planned · China
- Oct 30, 2023Phase 1 study in HealthyNCT06117514 · 82 enrolled · China
- Nov 18, 20242 phase 1 studiesNCT06701136, NCT06701110
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06701136Rifampicin-Resistant Pulmonary Tuberculosis Patients | 1 | Not yet recruiting | Oct 12, 2025 | 16 |
| NCT06701110TB · China | 1 | Recruiting | Dec 12, 2025 | 10 |
| NCT06117514Healthy · China | 1 | Completed | Jul 2, 2020 | 82 |
| NCT05824871Tuberculosis · China | 3 | Recruiting | Dec 22, 2025 | 450 |
| NCT04608955Tuberculosis, Pulmonary · China | 2 | Completed | Apr 13, 2022 | 99 |
How it is read
Names in the registry
- “Sudapyridine”, 2 entries
- “[U-14C] WX-081”, 1 entry
- “Sudapyridine 30mg”, 1 entry
- “Sudapyridine 100mg SAD”, 1 entry
- “Sudapyridine 200mg SAD”, 1 entry
Conditions, from the studies’ own filings
- Tuberculosis, Pulmonary, 2 studies
- Tuberculosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.